Surpass Flow Diverter in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue American Journal of Neuroradiology Année : 2015

Surpass Flow Diverter in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study

A.K. Wakhloo
  • Fonction : Auteur
P. Lylyk
  • Fonction : Auteur
J. de Vries
  • Fonction : Auteur
C. Taschner
  • Fonction : Auteur
J. Lundquist
  • Fonction : Auteur
M. Hartmann
  • Fonction : Auteur
I. Szikora
  • Fonction : Auteur
N. Sakai
  • Fonction : Auteur
H. Imamura
I. Rennie
  • Fonction : Auteur
M. Skalej
  • Fonction : Auteur
O. Beuing
  • Fonction : Auteur
F. Mery
  • Fonction : Auteur
P. Brouwer
  • Fonction : Auteur
E. Boccardi
  • Fonction : Auteur
L. Valvassori
  • Fonction : Auteur
S. Derakhshani
  • Fonction : Auteur
M.W. Litzenberg
  • Fonction : Auteur
M.J. Gounis
  • Fonction : Auteur
Surpass Study Group
  • Fonction : Auteur

Résumé

BACKGROUND AND PURPOSE: Incomplete occlusion and recanalization of large and wide-neck brain aneurysms treated by endovascular therapy remains a challenge. We present preliminary clinical and angiographic results of an experimentally optimized Surpass flow diverter for treatment of intracranial aneurysms in a prospective, multicenter, nonrandomized, single-arm study. MATERIALS AND METHODS: At 24 centers, 165 patients with 190 intracranial aneurysms of the anterior and posterior circulations were enrolled. The primary efficacy end point was the percentage of intracranial aneurysms with 100% occlusion on 6-month DSA. The primary safety end point was neurologic death and any stroke through a minimum follow-up of 6 months. RESULTS: Successful flow-diverter delivery was achieved in 161 patients with 186 aneurysms (98%); the mean number of devices used per aneurysm was 1.05. Clinical follow-up (median, 6 months) of 150 patients (93.2%), showed that the primary safety end point occurred in 18 subjects. Permanent neurologic morbidity and mortality were 6% and 2.7%, respectively. Morbidity occurred in 4% and 7.4% of patients treated for aneurysms of the anterior and posterior circulation, respectively. Neurologic death during follow-up was observed in 1.6% and 7.4% of patients with treated intracranial aneurysms of the anterior and posterior circulation, respectively. Ischemic stroke at ≤30 days, SAH at ≤7 days, and intraparenchymal hemorrhage at ≤7 days were encountered in 3.7%, 2.5%, and 2.5% of subjects, respectively. No disabling ischemic strokes at >30 days or SAH at >7 days occurred. New or worsening cranial nerve deficit was observed in 2.7%. Follow-up angiography available in 158 (86.8%) intracranial aneurysms showed 100% occlusion in 75%. CONCLUSIONS: Clinical outcomes of the Surpass flow diverter in the treatment of intracranial aneurysms show a safety profile that is comparable with that of stent-assisted coil embolization. Angiographic results showed a high rate of intracranial aneurysm occlusion.

Dates et versions

hal-02278470 , version 1 (04-09-2019)

Identifiants

Citer

A.K. Wakhloo, P. Lylyk, J. de Vries, C. Taschner, J. Lundquist, et al.. Surpass Flow Diverter in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study. American Journal of Neuroradiology, 2015, 36 (1), pp.98-107. ⟨10.3174/ajnr.A4078⟩. ⟨hal-02278470⟩
49 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More